These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 35450536)
1. Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease. Mazahir F; Yadav AK CNS Neurol Disord Drug Targets; 2023; 22(4):477-499. PubMed ID: 35450536 [TBL] [Abstract][Full Text] [Related]
2. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603 [TBL] [Abstract][Full Text] [Related]
3. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419 [TBL] [Abstract][Full Text] [Related]
4. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Sharma HS; Castellani RJ; Smith MA; Sharma A Int Rev Neurobiol; 2012; 102():47-90. PubMed ID: 22748826 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges. Iqbal I; Saqib F; Mubarak Z; Latif MF; Wahid M; Nasir B; Shahzad H; Sharifi-Rad J; Mubarak MS Eur J Med Res; 2024 Jun; 29(1):313. PubMed ID: 38849950 [TBL] [Abstract][Full Text] [Related]
6. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Banks WA Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501 [TBL] [Abstract][Full Text] [Related]
7. Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements. Shastri D; Raj V; Lee S Ageing Res Rev; 2024 Aug; 99():102379. PubMed ID: 38901740 [TBL] [Abstract][Full Text] [Related]
8. Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route. Tripathi S; Gupta U; Ujjwal RR; Yadav AK J Microencapsul; 2021; 38(7-8):572-593. PubMed ID: 34591731 [TBL] [Abstract][Full Text] [Related]
9. Nanomedicine for the treatment of Alzheimer's disease. Gregori M; Masserini M; Mancini S Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574 [TBL] [Abstract][Full Text] [Related]
10. [Role of the blood-brain barrier in Alzheimer's disease]. Gosselet F; Candela P; Cecchelli R; Fenart L Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026 [TBL] [Abstract][Full Text] [Related]
11. Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients. Bhattacharya S Curr Pharm Biotechnol; 2023; 24(9):1108-1121. PubMed ID: 36305141 [TBL] [Abstract][Full Text] [Related]
12. Biomaterials in treatment of Alzheimer's disease. Agrawal M; Prathyusha E; Ahmed H; Dubey SK; Kesharwani P; Singhvi G; Naidu VGM; Alexander A Neurochem Int; 2021 May; 145():105008. PubMed ID: 33684545 [TBL] [Abstract][Full Text] [Related]
13. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407 [TBL] [Abstract][Full Text] [Related]
14. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289 [TBL] [Abstract][Full Text] [Related]
15. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview. Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049 [TBL] [Abstract][Full Text] [Related]
16. Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis. Tashima T Chem Pharm Bull (Tokyo); 2020; 68(4):316-325. PubMed ID: 32238649 [TBL] [Abstract][Full Text] [Related]
17. Targeted Nanoparticles for the Treatment of Alzheimer's Disease. Martín-Rapun R; De Matteis L; Ambrosone A; Garcia-Embid S; Gutierrez L; de la Fuente JM Curr Pharm Des; 2017; 23(13):1927-1952. PubMed ID: 28025949 [TBL] [Abstract][Full Text] [Related]
18. β-Amyloid targeting nanodrug for neuron-specific delivery of nucleic acids in Alzheimer's disease mouse models. Israel LL; Sun T; Braubach O; Cox A; Shatalova ES; Rashid HM; Galstyan A; Grodzinski Z; Song XY; Chepurna O; Ljubimov VA; Chiechi A; Sharma S; Phebus C; Wang Y; Ljubimova JY; Black KL; Holler E J Control Release; 2023 Sep; 361():636-658. PubMed ID: 37544515 [TBL] [Abstract][Full Text] [Related]
19. Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease. Li L; Zhang J; Huang X; Du J; Tu Z; Wu H; Liu X; Yuan M Curr Pharm Des; 2023; 29(2):95-115. PubMed ID: 36529920 [TBL] [Abstract][Full Text] [Related]
20. Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer's, and Tumor Mouse Models. Israel LL; Galstyan A; Cox A; Shatalova ES; Sun T; Rashid MH; Grodzinski Z; Chiechi A; Fuchs DT; Patil R; Koronyo-Hamaoui M; Black KL; Ljubimova JY; Holler E ACS Nano; 2022 Aug; 16(8):11815-11832. PubMed ID: 35961653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]